757 studies found for:    "Esophageal cancer"
Show Display Options
Rank Status Study
1 Completed Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
Conditions: Esophageal Cancer;   Cancer of the Esophagus;   Esophagus Cancer;   Esophageal Neoplasm;   Cancer of Esophagus
Interventions: Drug: Irinotecan (drug);   Drug: Taxotere (drug);   Procedure: Radiotherapy (procedure);   Procedure: Esophagectomy (procedure)
2 Completed Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Recurrent Esophageal Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage III Esophageal Cancer;   Stage IV Esophageal Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
3 Recruiting Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;
Conditions: Esophageal Neoplasm;   Esophageal Cancer TNM Staging Primary Tumor (T) T2;   Esophageal Cancer TNM Staging Primary Tumor (T) T3;   Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0;   Esophageal Cancer TNM Staging Distal Metastasis (M) M0
Intervention: Radiation: Prophylactic postoperative radiation therapy
4 Recruiting Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
Interventions: Radiation: radiation therapy;   Drug: paclitaxel;   Drug: carboplatin;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
5 Active, not recruiting Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Occult Non-small Cell Lung Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Anaplastic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor;   Salivary Gland Poorly Differentiated Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Lung Dysplasia;   Stage 0 Esophageal Cancer;   Stage 0 Non-small Cell Lung Cancer;   Stage I Adenoid Cystic Carcinoma of the Oral Cavity;   Stage I Basal Cell Carcinoma of the Lip;   Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage I Lymphoepithelioma of the Nasopharynx;   Stage I Lymphoepithelioma of the Oropharynx;   Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage I Mucoepidermoid Carcinoma of the Oral Cavity;   Stage I Non-small Cell Lung Cancer;   Stage I Salivary Gland Cancer;   Stage I Squamous Cell Carcinoma of the Hypopharynx;   Stage I Squamous Cell Carcinoma of the Larynx;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Nasopharynx;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage I Verrucous Carcinoma of the Larynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage IA Esophageal Cancer;   Stage IB Esophageal Cancer;   Stage II Adenoid Cystic Carcinoma of the Oral Cavity;   Stage II Basal Cell Carcinoma of the Lip;   Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Lymphoepithelioma of the Oropharynx;   Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage II Mucoepidermoid Carcinoma of the Oral Cavity;   Stage II Non-small Cell Lung Cancer;   Stage II Salivary Gland Cancer;   Stage II Squamous Cell Carcinoma of the Hypopharynx;   Stage II Squamous Cell Carcinoma of the Larynx;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage II Verrucous Carcinoma of the Larynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Esophageal Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Esophageal Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
6 Recruiting Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: cyclodextrin-based polymer-camptothecin CRLX101;   Other: Laboratory biomarker analysis;   Other: Pharmacological studies
7 Recruiting Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Squamous Cell Carcinoma of the Esophagus;   Stage IA Esophageal Cancer;   Stage IA Gastric Cancer;   Stage IB Esophageal Cancer;   Stage IB Gastric Cancer;   Stage IIA Esophageal Cancer;   Stage IIA Gastric Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer
Interventions: Biological: bevacizumab;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
8 Active, not recruiting Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Squamous Cell Carcinoma of the Esophagus;   Stage II Esophageal Cancer;   Stage II Gastric Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: oxaliplatin;   Drug: fluorouracil;   Radiation: radiation therapy;   Procedure: conventional surgery;   Other: immunohistochemistry staining method;   Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: laboratory biomarker analysis;   Genetic: gene expression analysis;   Radiation: fludeoxyglucose F 18
9 Active, not recruiting Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Recurrent Esophageal Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IV Esophageal Cancer
Interventions: Biological: cixutumumab;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Terminated Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
Conditions: Esophageal Neoplasms;   Carcinoma, Squamous Cell;   Adenocarcinoma;   Esophageal Cancer
Interventions: Drug: Capecitabine (Xeloda);   Drug: [18-F] Fluorodeoxyglucose (FDG);   Drug: 5-Fluorouracil (5-FU);   Drug: Carboplatin
11 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis
12 Terminated A Phase I/II Study of Genasense (G3139) in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Biological: oblimersen sodium;   Other: laboratory biomarker analysis;   Drug: cisplatin;   Drug: fluorouracil
13 Completed Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Primary Hepatocellular Carcinoma;   Adult Subependymoma;   Advanced Adult Primary Liver Cancer;   Advanced Malignant Mesothelioma;   Male Breast Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Malignant Mesothelioma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage II Esophageal Cancer;   Stage II Pancreatic Cancer;   Stage III Esophageal Cancer;   Stage III Pancreatic Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Anal Cancer;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
14 Recruiting Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy
Conditions: Esophageal Carcinoma;   Esophageal Cancer
Intervention: Procedure: Esophagectomy
15 Active, not recruiting Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis
16 Active, not recruiting Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: pralatrexate;   Drug: oxaliplatin;   Other: pharmacogenomic studies;   Genetic: RNA analysis;   Genetic: polymorphism analysis;   Genetic: polymerase chain reaction;   Genetic: microarray analysis;   Procedure: esophagogastroduodenoscopy;   Procedure: biopsy;   Other: laboratory biomarker analysis
17 Unknown  Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: Paclitaxel;   Drug: Capecitabine
18 Unknown  Genetic and Environmental Risk Factors Related to Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
19 Completed Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: cisplatin;   Drug: fluorouracil;   Drug: paclitaxel;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
20 Completed Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Interventions: Drug: cisplatin;   Drug: irinotecan hydrochloride;   Radiation: radiation therapy

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years